

**Top 10 Drug Classes and Subclasses
PPO and HMO Plans Carved Out to PBM 2016**

Rank	Drug Class and Sub-Classes	Estimated Reduction in Spending (in millions)
1	Insulins	\$3.4
	Insulin Analogs - Rapid Acting	\$1.6
	Insulin Analogs - Long Acting	\$1.5
	Insulin Analogs - Fixed Combinations	\$0.1
	Human Insulins - Short Acting	\$0.1
	Human Insulins - Intermediate Acting	\$0.0
	Human Insulins - Fixed Combinations	\$0.0
2	Skin and Mucous Membrane Agents, Misc	\$2.1
	Antipsoriatic Agents - MC Antibody, Human Interleukin 12/23 Inhibitors	\$1.0
	Antipsoriatic Agents - MC Antibody, Interleukin-17A Antagonist	\$0.3
	Acne Therapy Systemic - Retinoids & Derivatives	\$0.2
	Tetracycline Antibiotics	\$0.1
	Dermatological - Antineoplastic Antimetabolites	\$0.1
	Dermatological - Calcineurin Inhibitors	\$0.1
	Dermatological - Antipsoriatic Agents Topical	\$0.1
	Acne Therapy Topical - Retinoid Combinations Other	\$0.1
	Acne Therapy Topical - Retinoids & Derivatives	\$0.0
	Acne Therapy Topical - Anti-infective	\$0.0
	Dermatological - Immunomodulator - Imidazoquinolinamines	\$0.0
	Dermatological - Antineoplastic or Premalignant Lesions - Diterpene Esters	\$0.0
	Dermatological - Emollient Mixtures	\$0.0
	Dermatological - Eyelid Cleansers	\$0.0
	Dermatological - Antipsoriatic Agents Systemic, Vitamin A Derivatives	\$0.0
	Dermatological - Photodynamic Therapy Agents Topical	\$0.0
	Dermatological - Antineoplastic Selective Retinoid X Receptor Agonist	\$0.0
	Anal Fissure Pain/Treatment Agents - Nitrates	\$0.0
	Dermatological - Immunomodulator - Catechins - Genital Wart/HPV Tx	\$0.0
	Dermatological - Keratolytic-Antimitotic Single Agents	\$0.0
	Dermatological - Protectants	\$0.0
	Dermatological - Rosacea Therapy, Topical	\$0.0
	Acne Therapy Topical - Anti-infective-Retinoid Combinations	\$0.0
	Wound Care Combinations Other	\$0.0
	Wound Care - Cleanser Combinations	\$0.0
	Nail Protectives	\$0.0
	Dermatological - Antineoplastic Alkylating Agents	\$0.0
	Dermatological Irritants-Counter-Irritant Single Agents	\$0.0

Rank	Drug Class and Sub-Classes	Estimated Reduction in Spending (in millions)
	Dermatological - Antineoplastic or Premalignant Lesions - NSAID's	\$0.0
	Dermatological - Ornithine Decarboxylase (ODC) Inhibitors	\$0.0
	Wound Care - Dressings	\$0.0
	Hair Growth Agents - Type II 5-Alpha Reductase Inhibitors	\$0.0
3	Selective beta-2-Adrenergic Agonists	\$1.9
	Asthma/COPD Therapy - Beta Adrenergic-Glucocorticoid Combinations	\$1.2
	Asthma/COPD Therapy - Beta 2-Adrenergic Agents, Inhaled, Short Acting	\$0.5
	Asthma/COPD Therapy - Beta Adrenergic-Anticholinergic Combinations	\$0.1
	Asthma/COPD Therapy - Beta 2-Adrenergic Agents, Inhaled, Long Acting	\$0.0
	Asthma/COPD Therapy - Beta Adrenergic Agents	\$0.0
4	Incretin Mimetics	\$1.7
	Antihyperglycemic, Incretin Mimetic, GLP-1 Receptor Agonist Analog-Type	\$1.7
	Anti-Obesity - Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists	\$0.0
5	Anticonvulsants, Miscellaneous	\$1.5
	Anticonvulsant - GABA Analogs	\$0.7
	Anticonvulsant - Functionalized Amino Acid	\$0.2
	Anticonvulsant - Phenyltriazine Derivatives	\$0.1
	Anticonvulsant - Iminostilbene Derivatives	\$0.1
	Anticonvulsant - Monosaccharide Derivatives	\$0.1
	Anticonvulsant - GABA Transaminase (GABA-T) Inhibitor	\$0.1
	Anticonvulsant - Pyrrolidine Derivatives	\$0.0
	Anticonvulsant - Triazole Derivatives	\$0.0
	Anticonvulsant - Carboxylic Acid Derivatives	\$0.0
	Anticonvulsant - AMPA-Type Glutamate Receptor Antagonists	\$0.0
	Movement Disorder Therapy - Restless Legs Syndrome	\$0.0
	Anticonvulsant - Carbamates	\$0.0
	Bipolar Therapy Agents - Anticonvulsant Type	\$0.0
	Anticonvulsant - Sulfonamide Derivatives	\$0.0
6	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	\$1.5
	Antihyperglycemic - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	\$1.1
	Antihyperglycemic-Dipeptidyl Peptidase-4 (DPP-4) Inhibitor & Biguanide	\$0.4
7	Adrenals	\$1.1
	Asthma Therapy - Glucocorticoids	\$0.6
	Asthma/COPD Therapy - Beta Adrenergic-Glucocorticoid Combinations	\$0.5
	Inflammatory Bowel Agent - Glucocorticoids	\$0.1
	Glucocorticoids	\$0.0

**Top 10 Drug Classes and Subclasses
PPO and HMO Plans Carved Out to PBM 2016**

Rank	Drug Class and Sub-Classes	Estimated Reduction in Spending (in millions)
	Mineralocorticoids	\$0.0
	Glucocorticoid-Anesthetic Combinations	\$0.0
	Glucocorticoid Salt Combinations	\$0.0
8	Estrogens	\$1.1
	Estrogens	\$0.5
	Vaginal Estrogens	\$0.4
	Estrogen-Progestin	\$0.2
	Estrogen & Progestin with Antimineralocorticoid Activity, Combinations	\$0.0
	Estrogen-Androgen	\$0.0
9	Corticosteroids	\$0.8
	Dermatological - Glucocorticoid	\$0.4
	Ophthalmic - Anti-inflammatory, Glucocorticoids	\$0.1
	Otic - Anti-infective-Glucocorticoid Combinations	\$0.1
	Antipsoriatic - Vitamin D Analog - Glucocorticoid Combinations	\$0.1
	Nasal Corticosteroids	\$0.1
	Ophthalmic - Antibacterial-Glucocorticoid Combinations	\$0.0
	Anorectal - Glucocorticoids	\$0.0
	Dermatological - Antifungal-Glucocorticoid Combinations	\$0.0
	Otic - Glucocorticoids	\$0.0
	Mouth and Throat - Glucocorticoids	\$0.0
	Inflammatory Bowel Agent - Glucocorticoids	\$0.0
	Dermatological - Antibacterial-Glucocorticoid Combinations	\$0.0
	Dermatological - Glucocorticoid-Emollient Combinations	\$0.0
	Dermatological - Glucocorticoid-Skin Cleanser Combinations	\$0.0
	Dermatological - Glucocorticoid-Local Anesthetic Combinations	\$0.0
10	Atypical Antipsychotics	\$0.7
	Antipsychotic - Atypical Dopamine-Serotonin Antag- Benzisothiazolones	\$0.5
	Antipsychotic - Atypical Dopamine Partial Agonist-Serotonin Mixed	\$0.1
	Bipolar Therapy Agents - Atypical Antipsychotics	\$0.1
	Antipsychotic - Atypical Dopamine-Serotonin Antag- Benzisoxazole Deriv	\$0.0
	Antipsychotic -Atypical Dopamine-Serotonin Antag-Dibenzothiazepine Der	\$0.0
	Antipsychotic -Atypical Dopamine-Serotonin Antag-Thienobenzodiazepines	\$0.0
	Antipsychotic - Atypical Dopamine-Serotonin Antag-Dibenzodiazepine Der	\$0.0
	Total	\$15.8